| abstract |
Platelet activating factor antagonists of formula (I): ##STR1## wherein R is phenyl or phenyl substituted by one or more substituents selected from nitro, halo, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl(C 1 -C 4 )alkoxy, fluoro(C 1 -C 4 )alkoxy, C 1 -C 4 alkylthio, C 1 -C 4 alkylsulphonyl, hydroxy, trifluoromethyl and cyano, or is phenyl fused to a dioxole ring; n R 1 and R 2 are each independently H or C 1 -C 6 alkyl, or R 1 and R 2 together complete a pyrrolidinyl, piperidino, morpholino, piperazinyl, N-(C 1 -C 4 alkyl)piperazinyl or N-(C 2 -C 4 alkanoyl)-piperazinyl group; n R 2 is H or C 1 -C 4 alkyl and R 1 is CN, C 3 -C 7 cycloalkyl, aryl, heteroaryl or a C 1 -C 4 alkyl group substituted by one or more substituents selected from C 3 -C 7 cycloalkyl, C 1 -C 4 alkoxycarbonyl, aryl or heteroaryl; n Z is selected from C 1 -C 6 alkoxy, aryl(C 1 -C 4 )alkoxy, hydroxy, and --NR 4 R 5 wherein each of R 4 and R 5 is independently H or C 1 -C 6 alkyl, or R 4 and R 5 together complete a pyrrolidinyl, piperidino, morpholino, piperazinyl or N-(C 1 -C 4 alkyl)piperazinyl group; Y is 1,4 phenylene or pyridine-2,5-diyl, n X is a 5 or 6 membered aromatic heterocyclic group containing one or more nitrogen atoms in its ring; which ring may be fused to a benzene ring or to a further 5- or 6-membered aromatic heterocyclic ring containing one or more nitrogen atoms, at least one of said heterocyclic rings optionally also containing an oxygen or sulphur atom, and being optionally substituted with one or more substituents selected from C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halo, CF 3 and CN; n and their pharmaceutically acceptable salts. |